论文部分内容阅读
美国食品和药物管理局 ( FDA)已批准 Hoffmann- L a Roche公司的聚乙二醇 -α2 a干扰素 ( Pegasys)用于治疗成人慢性丙型肝炎患者 ,后者罹患代偿性肝病 ,以前未接受过 α干扰素治疗。该制品是基于在 1 50 0例成人患者中进行的三项开放性随机对照研究的结果而获准使用的。所有患
The U.S. Food and Drug Administration (FDA) has approved Hoffmann-La Roche’s Pegasys for the treatment of adults with chronic hepatitis C who have compensated liver disease without previous Have received interferon alpha treatment. The product was approved for use as a result of three open-label randomized controlled studies in 150 adult patients. All suffering